Caribou Biosciences Appoints Scott Braunstein, M.D. to Board of Directors
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has appointed Scott Braunstein, M.D.
- Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has appointed Scott Braunstein, M.D.
- It is a great privilege to welcome Scott to our board of directors, said Rachel Haurwitz, Ph.D., president and chief executive officer of Caribou.
- Dr. Braunstein currently serves as chief executive officer and on the board of directors of Marinus Pharmaceuticals, a company dedicated to the development of innovative therapeutics that treat rare seizure disorders.
- Caribou Biosciences and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005401/en/